Are Analysts Bullish about Portola Pharmaceuticals Inc (NASDAQ:PTLA) after last week?

November 15, 2017 - By reb123z

 Are Analysts Bullish about Portola Pharmaceuticals Inc (NASDAQ:PTLA) after last week?
Investors sentiment decreased to 1.31 in Q2 2017. Its down 0.29, from 1.6 in 2017Q1. It dived, as 17 investors sold Portola Pharmaceuticals Inc shares while 58 reduced holdings. 45 funds opened positions while 53 raised stakes. 48.64 million shares or 0.79% more from 48.26 million shares in 2017Q1 were reported.
Profund Advisors Ltd Company holds 0.06% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 23,074 shares. Fortaleza Asset Inc holds 2,880 shares or 0.31% of its portfolio. Alps Advsr Inc reported 51,468 shares stake. 7,870 are owned by Perceptive Advsrs Ltd Liability Corporation. Next Finance holds 0% in Portola Pharmaceuticals Inc (NASDAQ:PTLA) or 100 shares. 225,385 were accumulated by Voya Limited Liability Co. California State Teachers Retirement Sys reported 0.01% stake. Northern Corp, Illinois-based fund reported 635,998 shares. Tower Rech Capital Ltd Limited Liability Company (Trc) invested 0% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Rock Springs Cap L P stated it has 139,700 shares or 0.4% of all its holdings. Paradigm Asset Company Limited Liability accumulated 0% or 11,800 shares. Castleark Ltd invested in 0.08% or 42,286 shares. Schwab Charles Management Inc holds 228,187 shares. Laurion Mngmt L P holds 52,500 shares. Adage Capital Ptnrs Group Inc Ltd Liability Company stated it has 0.01% in Portola Pharmaceuticals Inc (NASDAQ:PTLA).

Since May 31, 2017, it had 1 buy, and 1 insider sale for $54.68 million activity. 1.70 million Portola Pharmaceuticals Inc (NASDAQ:PTLA) shares with value of $58.48 million were sold by Maxwell (Mauritius) Pte Ltd.

Portola Pharmaceuticals Inc (NASDAQ:PTLA) Ratings Coverage

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Portola Pharmaceuticals had 28 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co with “Buy” on Wednesday, August 9. The company was downgraded on Friday, August 19 by Citigroup. Credit Suisse maintained the stock with “Buy” rating in Wednesday, September 20 report. Credit Suisse maintained the shares of PTLA in report on Tuesday, December 27 with “Outperform” rating. The stock has “Buy” rating by Citigroup on Tuesday, January 3. The firm earned “Buy” rating on Wednesday, August 5 by Cowen & Co. The stock has “Buy” rating by Goldman Sachs on Friday, December 18. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) has “Outperform” rating given on Thursday, August 24 by Credit Suisse. The firm earned “Overweight” rating on Friday, October 6 by Morgan Stanley. The firm earned “Neutral” rating on Monday, March 28 by Goldman Sachs. Below is a list of Portola Pharmaceuticals Inc (NASDAQ:PTLA) latest ratings and price target changes.

06/10/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $75 New Target: $81 Maintain
20/09/2017 Broker: Credit Suisse Rating: Buy New Target: $70.0 Maintain
28/08/2017 Broker: Oppenheimer Rating: Buy New Target: $80.0 Maintain
24/08/2017 Broker: Credit Suisse Old Rating: Neutral New Rating: Outperform Upgrade
10/08/2017 Broker: Credit Suisse Rating: Hold New Target: $70.0000 Maintain
10/08/2017 Broker: Oppenheimer Rating: Buy New Target: $80.0000 Maintain
09/08/2017 Broker: Cowen & Co Rating: Buy New Target: $70.0000 Maintain
04/08/2017 Broker: Oppenheimer Rating: Buy New Target: $80.0000 Maintain
23/07/2017 Broker: Oppenheimer Rating: Buy New Target: $80.0000 Maintain
26/06/2017 Broker: Morgan Stanley Rating: Buy New Target: $70.0000 Maintain

About shares traded. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has risen 51.17% since November 15, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $3.07 billion. The Firm is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. It currently has negative earnings. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

More notable recent Portola Pharmaceuticals Inc (NASDAQ:PTLA) news were published by: Nasdaq.com which released: “Commit To Purchase Portola Pharmaceuticals At $40, Earn 17.2% Annualized Using …” on October 25, 2017, also Globenewswire.com with their article: “Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and …” published on October 30, 2017, Seekingalpha.com published: “Portola Pharmaceuticals: A Low-Quality Stock Or Simply Misunderstood?” on November 07, 2017. More interesting news about Portola Pharmaceuticals Inc (NASDAQ:PTLA) were released by: Globenewswire.com and their article: “Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and …” published on November 06, 2017 as well as Globenewswire.com‘s news article titled: “Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on …” with publication date: November 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.